First Patient Dosed in Innocare’s Prurigo Nodularis Trial
InnoCare has dosed the first patient in a global Phase II trial of its oral TYK2 inhibitor, soficitinib (ICP-332),...
Silexion Completes SIL204 Toxicology for Pancreatic Cancer
Two-species toxicology for Silexion’s siRNA candidate SIL204 reported no systemic organ toxicity, clearing a key preclinical gate and keeping...
Tempest Closes Up To $8.35M Registered Direct Offering
Tempest Therapeutics closed a registered direct offering of 1,172,414 shares at $3.625 per share for approximately $4.25 million in...
Hutchmed Highlights Data for ESMO Asia, ASH 2025 Meetings
No efficacy or safety figures were disclosed ahead of the meetings, but HUTCHMED will take a broad slate of...
First Patient Dosed in Phase II Prurigo Nodularis Trial
InnoCare has dosed the first patient in a global Phase II study of Soficitinib (ICP-332), a selective TYK2 inhibitor,...
Dipharma’s Novel Approach to Nitrosamine Detection in APIs
Dipharma reports a new analytical approach that combines 15N‑enriched nitrosating reagents with 15N NMR readout to selectively detect and...
Hutchmed Highlights New Clinical Data for 2025 ESMO & ASH
HUTCHMED will take a multi-asset slate to ESMO Asia and ASH in early December, flagging new and updated readouts...
Xenon to Present New Azetukalner Epilepsy Data at AES 2025
A ≥48-month interim analysis from Xenon’s ongoing seven-year X-TOLE open-label extension will be featured at AES 2025, focusing on...
Scilex Holding Completes Equity Financing in Datavault AI
Scilex has exercised a pre-funded warrant for 263,914,094 shares of Datavault AI, a stake valued at approximately $583.3 million...
Celcuity to Present Updated VIKTORIA-1 Data at SABCS 2025
No new efficacy numbers were disclosed, but Celcuity will present updated subgroup and safety results from the randomized Phase...